` BYSI (Beyondspring Inc) vs S&P 500 Comparison - Alpha Spread

BYSI
vs
S&P 500

Over the past 12 months, BYSI has underperformed S&P 500, delivering a return of +9% compared to the S&P 500's +15% growth.

Stocks Performance
BYSI vs S&P 500

Loading
BYSI
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
BYSI vs S&P 500

Loading
BYSI
S&P 500
Difference
www.alphaspread.com

Performance By Year
BYSI vs S&P 500

Loading
BYSI
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Beyondspring Inc vs Peers

S&P 500
BYSI
ABBV
AMGN
GILD
VRTX
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Beyondspring Inc
Glance View

Market Cap
70.2m USD
Industry
Biotechnology

BeyondSpring, Inc. engages in the the development and commercialization of immuno-oncology cancer therapies to improve clinical outcomes for patients who have high unmet medical needs. The company is headquartered in New York City, New York and currently employs 103 full-time employees. The company went IPO on 2017-03-09. The Company’s lead product Plinabulin, which is being studied as an anti-cancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC). The Plinabulin product is a marine-derived small-molecule selective immunomodulating microtubule-binding agent (SIMBA) with a range of immune activities. Its Plinabulin has the immune defense protein, GEF-H1, which leads to two effects: a durable anti-cancer benefits due to the maturation of dendritic cells resulting in activation of tumor antigen-specific T-cells to target cancer cells and early-onset action in chemotherapy-induced neutropenia (CIN) prevention after chemotherapy by boosting the number of hematopoietic stem/progenitor cells (HSPCs).

BYSI Intrinsic Value
Not Available
Back to Top